Breast cancers from patients who had high-level expression of ROR1 had a worse EFS when adjusted for subtype and treatment arm (HR 1.2, 95% CI = 1.03–1.40, LRp = 0.02), Table 1. This evidence concerns the gene ROR1 and breast carcinoma.